Breaking News

inVentiv To Acquire Ingenix Clinical Units

January 20, 2011

inVentiv Health has signed a definitive agreement to acquire the i3 clinical development businesses from Ingenix.

inVentiv Health has signed a definitive agreement to acquire the i3 clinical development businesses from Ingenix. The transaction, subject to customary closing conditions, is expected to close in 1H11.

The three businesses will retain the i3 brand and will be aligned with inVentiv’s other clinical development offerings. Glenn Bilawsky will remain chief executive officer of i3. The commercialization, safety, regulatory and late phase service offerings will be launched as Ingenix Life Sciences division, led by Lee Valenta, chief operating officer of Ingenix.

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks